TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28845931

Group type: EXPERIMENTAL
Intervention: Adjuvant antioxidant therapy with SpermActin-forte (SA)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Adjuvant antioxidant therapy with SpermActin-forte (SA) and vitamin complex (VC)
Number of subjects: 114

Group type: COMPARATOR
Intervention: No adjuvant therapy (Control)
Number of subjects: 114
Study: 25727806

Group type: EXPERIMENTAL
Intervention: Active support
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Passive support
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (intimacy effect)
Number of subjects: 80
Study: 25117173

Group type: EXPERIMENTAL
Intervention: Daclatasvir 60 mg once daily and asunaprevir 200 mg twice daily (combination dosing for 14 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Daclatasvir and asunaprevir administered together or alone in HCV patients
Number of subjects: 0
Study: 22159659

Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 894
Study: 21949794

Group type: EXPERIMENTAL
Intervention: Head-down bed rest (BR)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sitting control condition
Number of subjects: 20
Study: 18041485

Group type: EXPERIMENTAL
Intervention: 10 mg zolpidem
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 mg zaleplon
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 16119487

Group type: EXPERIMENTAL
Intervention: S-ketamine (1 mg/kg) with priming (0.04 mg/kg of rocuronium)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: S-ketamine (1 mg/kg) without priming
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Thiopentone (4 mg/kg) with priming (0.04 mg/kg of rocuronium)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Thiopentone (4 mg/kg) without priming
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (sham priming with saline) with S-ketamine (1 mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (sham priming with saline) with thiopentone (4 mg/kg)
Number of subjects: 60
Study: 12296586

Group type: EXPERIMENTAL
Intervention: Daily treatment (full-mouth daily scaling and root planing for 4 consecutive days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Weekly treatment (once a week for 4 weeks)
Number of subjects: 100
Study: 10073377

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional antipsychotic drugs
Number of subjects: 0
Study: 8629068

Group type: EXPERIMENTAL
Intervention: mebendazole plus pyrantel oxantel pamoate every three months
Number of subjects: 353

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 353
Study: 2202705

Group type: EXPERIMENTAL
Intervention: Sucralfate 1 g four times daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sucralfate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 0
Study: 6110957

Group type: EXPERIMENTAL
Intervention: Nicotinic acid (25 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benorylate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naloxone
Number of subjects: 0
Study: 30912713

Group type: EXPERIMENTAL
Intervention: Experimental Group (EG): autonomy supportive teaching enriched with high levels of competence support and relatedness support
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control Group (CG): autonomy supportive teaching enriched with basic levels of competence support and relatedness support
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Both groups assessed at three time points (T1, T2, T3) for perceived moderation competence and emotions, with grades from a practical moderation exam at T3.
Number of subjects: 160
Study: 28220040

Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 236
Study: 25290685

Group type: EXPERIMENTAL
Intervention: Telemedicine advice on wound management
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional practice
Number of subjects: 90
Study: 24074879

Group type: EXPERIMENTAL
Intervention: NPLD (60 mg/mq iv) plus cyclophosphamide (600 mg/mq iv) every 3 weeks for 4 cycles followed by docetaxel (35 mg/mq iv) plus trastuzumab (4 mg/mq loading dose iv, then 2 mg/mq iv) weekly for 16 weeks
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: CT-PET
Number of subjects: 43
Study: 21356075

Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 156

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 156
Study: 19648746

Group type: EXPERIMENTAL
Intervention: Complete removal of carious dentin using a caries detector dye
Number of subjects: 32

Group type: COMPARATOR
Intervention: Partial removal of carious dentin (only superficial removal of necrotic carious dentin from the cavity floor)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups after sealing
Number of subjects: 32
Study: 17465348

Group type: EXPERIMENTAL
Intervention: Grafted group (autogenous bone harvested from the mandibular symphysis)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nongrafted group (no grafting)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 15
Study: 15452611

Group type: EXPERIMENTAL
Intervention: Epithalamin (peptide preparation from the pineal gland)
Number of subjects: 0
Study: 11552904

Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg b.d.
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg o.m.
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg o.m.
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 9041069

Group type: EXPERIMENTAL
Intervention: Balke treadmill protocol
Number of subjects: 38

Group type: COMPARATOR
Intervention: Bruce treadmill protocol
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Gender comparison
Number of subjects: 38
Study: 7932809

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 62

Group type: COMPARATOR
Intervention: No-tamoxifen
Number of subjects: 62
Study: 3177073

Group type: EXPERIMENTAL
Intervention: Free smoking in a structured context
Number of subjects: 0
Study: 30449654

Group type: EXPERIMENTAL
Intervention: High goal impact condition
Number of subjects: 68

Group type: COMPARATOR
Intervention: Low goal impact condition
Number of subjects: 68
Study: 27063478

Group type: EXPERIMENTAL
Intervention: Ambrisentan (10 mg per day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 24943851

Group type: EXPERIMENTAL
Intervention: Integrated treatment Simultaneously Targeting Obesity and Pain (STOP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care behavioral weight loss
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care behavioral pain management
Number of subjects: 0
Study: 22627057

Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate suspension 0.2% administered QID
Number of subjects: 300

Group type: COMPARATOR
Intervention: Olopatadine solution 0.1% administered BID
Number of subjects: 300
Study: 20689824

Group type: EXPERIMENTAL
Intervention: Leflunomide for 28 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 19137888

Group type: EXPERIMENTAL
Intervention: Open reduction and pulling out wire (Group A)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Percutaneous pinning with plaster splint (Group B)
Number of subjects: 72
Study: 15869587

Group type: EXPERIMENTAL
Intervention: Second generation oral contraceptives
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Third generation oral contraceptives
Number of subjects: 7
Study: 12534456

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg day-1 for 3 weeks
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 9588621

Group type: EXPERIMENTAL
Intervention: Fat Meal (FM)
Number of subjects: 9
Study: 8570773

Group type: EXPERIMENTAL
Intervention: Biperiden (Akineton) 12 mg/day for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glycopyrrolate (Robinul) 1 mg/day for 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biperiden (Akineton) 12 mg/day for 1 week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 1 week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 1 week (week 6)
Number of subjects: 0
Study: 1700927

Group type: EXPERIMENTAL
Intervention: Combined modality therapy (chemotherapy followed by radiation therapy)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 46
Study: 535132

Group type: EXPERIMENTAL
Intervention: Divided dose regimen of 25 mg methotrexate taken at 2-hour intervals (total 100 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single 100 mg oral dose of methotrexate
Number of subjects: 0
Study: 31586602

Group type: EXPERIMENTAL
Intervention: Minimally invasive radical hysterectomy (n=279)
Number of subjects: 631

Group type: COMPARATOR
Intervention: Open radical hysterectomy (n=257)
Number of subjects: 631
Study: 31789301

Group type: EXPERIMENTAL
Intervention: Proprioceptive-visual feedback during walking for 30 minutes, 3 times/week for 8 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Regular therapeutic exercise program for 1 hour, walking for 30 minutes without feedback
Number of subjects: 30
Study: 27439114

Group type: EXPERIMENTAL
Intervention: Lauromacrogol-cyanoacrylate-lauromacrogol
Number of subjects: 96

Group type: COMPARATOR
Intervention: Lipiodol-cyanoacrylate-lipiodol
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 96
Study: 25867230

Group type: EXPERIMENTAL
Intervention: Functional training (FT) program consisting of two sessions a week of in-water exercise and one of on-land exercise for 18 weeks
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Functional training (FT) program
Number of subjects: 36
Study: 23593417

Group type: EXPERIMENTAL
Intervention: rhGH 3 mg daily
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: rosiglitazone 4 mg twice daily
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Combination rhGH + rosiglitazone
Number of subjects: 77

Group type: COMPARATOR
Intervention: Double placebo (control)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: rhGH/rosiglitazone
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: rhGH
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: rosiglitazone alone
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 77
Study: 21831993

Group type: COMPARATOR
Intervention: SFA-rich drinks
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: SFA + LC n-3 PUFA (DHA-rich fish oil)
Number of subjects: 59
Study: 20095368

Group type: EXPERIMENTAL
Intervention: D-cycloserine 100 mg
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 17118091

Group type: EXPERIMENTAL
Intervention: Opioids (MS-contin, methadone)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 14985219

Group type: EXPERIMENTAL
Intervention: 100 mg FeSO(4)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 11556862

Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency thermal ablation tonsillectomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional cold dissection tonsillectomy with diathermy hemostasis
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 40
Study: 10101526

Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray (0.56 mg intranasally daily for two weeks)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 7828351

Group type: EXPERIMENTAL
Intervention: Growth hormone therapy for 4 months
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo treatment for 4 months
Number of subjects: 21
Study: 2455153

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 24
Study: 30415813

Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg/d and Solifenacin 10 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg/d and Solifenacin 20 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dutasteride 0.5 mg/d
Number of subjects: 0
Study: 26754620

Group type: EXPERIMENTAL
Intervention: Endonasal spreader graft surgery with septoplasty and turbinoplasty
Number of subjects: 17
Study: 25106783

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT-D)
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: Baseline galectin-3 level
Number of subjects: 654
Study: 24066322

Group type: EXPERIMENTAL
Intervention: Atraumatic flapless procedure
Number of subjects: 19

Group type: COMPARATOR
Intervention: Conventional flap procedure
Number of subjects: 19
Study: 21998206

Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA)
Number of subjects: 19
Study: 18466078

Group type: EXPERIMENTAL
Intervention: Treatment of hyperthyroidism
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Treatment of hypothyroidism
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 47
Study: 16549905

Group type: EXPERIMENTAL
Intervention: AST-120 (3 g t.i.d.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12735499

Group type: EXPERIMENTAL
Intervention: Watchful waiting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pre-PSA era survival analysis
Number of subjects: 0
Study: 10959787

Group type: EXPERIMENTAL
Intervention: Enamel Matrix Derivative (Emdogain)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Guided Tissue Regeneration (GTR) with ePTFE membranes
Number of subjects: 30

Group type: COMPARATOR
Intervention: Widman Modified Flap (WMF)
Number of subjects: 30
Study: 8874307

Group type: COMPARATOR
Intervention: Blind manual bedside method
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Sonographic bedside technique
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Sonographic technique
Number of subjects: 35
Study: 1408537

Group type: EXPERIMENTAL
Intervention: Double phototherapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Single phototherapy
Number of subjects: 70
Study: 2821151

Group type: EXPERIMENTAL
Intervention: High cereal fibre diet
Number of subjects: 201

Group type: COMPARATOR
Intervention: Low cereal fibre diet
Number of subjects: 201
Study: 29651953

Group type: EXPERIMENTAL
Intervention: Partly supervised cardiac rehabilitation (G1)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Supervised cardiac rehabilitation (G2)
Number of subjects: 61
Study: 27754709

Group type: EXPERIMENTAL
Intervention: Enzyme-Modified Ginseng Extract (EMGE) 2,000 mg/day for 4 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 24038817

Group type: EXPERIMENTAL
Intervention: Additional stenting for side branch dissections
Number of subjects: 117

Group type: COMPARATOR
Intervention: Conservative management (no stenting) for side branch dissections
Number of subjects: 117

Group type: COMPARATOR
Intervention: Patients without side branch dissections
Number of subjects: 117
Study: 23363720

Group type: EXPERIMENTAL
Intervention: Intensive intervention (4 CAD lectures, CAD outpatient visit twice a month, monthly telephone instructions)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Intensive intervention
Number of subjects: 263
Study: 20728691

Group type: EXPERIMENTAL
Intervention: Individualizing student instruction (ISI)
Number of subjects: 445

Group type: COMPARATOR
Intervention: Control group (business-as-usual)
Number of subjects: 445
Study: 18264012

Group type: EXPERIMENTAL
Intervention: Subcutaneous histamine (1‐10 ng twice a week)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Oral topiramate (100 mg daily)
Number of subjects: 90
Study: 19841763

Group type: EXPERIMENTAL
Intervention: High frequency ultrasonic agitation applied with a 1 MHz therapeutic ultrasonic device on the dentin surfaces using G-Bond adhesive.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High frequency ultrasonic agitation applied with a 1 MHz therapeutic ultrasonic device on the dentin surfaces using Futurabond adhesive.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High frequency ultrasonic agitation applied with a 1 MHz therapeutic ultrasonic device on the dentin surfaces using Clearfil S3 Bond adhesive.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group using bonding procedures according to manufacturers' instructions for G-Bond adhesive.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group using bonding procedures according to manufacturers' instructions for Futurabond adhesive.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group using bonding procedures according to manufacturers' instructions for Clearfil S3 Bond adhesive.
Number of subjects: 36
Study: 15206986

Group type: EXPERIMENTAL
Intervention: Solifenacin (10 mg) administered in fasting state
Number of subjects: 24

Group type: COMPARATOR
Intervention: Solifenacin (10 mg) administered in fed state
Number of subjects: 24
Study: 11324372

Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 2100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2100
Study: 9134633

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation (INR 2.5-4.0)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heparin administration (APTT 1.5-2.5 x control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Untreated subjects with congenital antithrombin deficiency
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women using oral contraceptives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deep vein thrombosis (phlebographically confirmed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coronary artery disease (angiographically assessed)
Number of subjects: 0
Study: 7898965

Group type: EXPERIMENTAL
Intervention: Surfactant therapy (two doses of Exosurf rescue surfactant)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Air placebo (two doses of air)
Number of subjects: 10
Study: 3112934

Group type: EXPERIMENTAL
Intervention: Penicillin levels above the MIC of alfa-streptococci
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Penicillin levels above the MIC of beta-streptococci but below that of alfa-strains
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ordinary sugar coated penicillin tablets
Number of subjects: 0
Study: 30666859

Group type: EXPERIMENTAL
Intervention: Bioptron light treatment in addition to full mouth scaling and root planing (FMSRP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Full mouth scaling and root planing (FMSRP)
Number of subjects: 40
Study: 29157258

Group type: EXPERIMENTAL
Intervention: Earplugs and eye mask
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Earplugs and eye mask (when worn all night)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (no earplugs and eye mask)
Number of subjects: 64
Study: 26188623

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0
Study: 23608139

Group type: EXPERIMENTAL
Intervention: Upper respiratory tract illness (URTI) with high stress exposure
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Upper respiratory tract illness (URTI) with low stress exposure
Number of subjects: 356

Group type: COMPARATOR
Intervention: Healthy individuals (no URTI)
Number of subjects: 356
Study: 21157021

Group type: EXPERIMENTAL
Intervention: Memantine (10 mg bid)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 18984667

Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg daily for 6 months
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 16505499

Group type: EXPERIMENTAL
Intervention: 500 or 1,000 mcg chromium daily (chromium picolinate)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 14765284

Group type: EXPERIMENTAL
Intervention: Alpha-santalol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: East Indian sandalwood oil
Number of subjects: 0
Study: 11757828

Group type: EXPERIMENTAL
Intervention: 1.5 L fill volume
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 2.0 L fill volume
Number of subjects: 21
Study: 9153171

Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication
Number of subjects: 110

Group type: COMPARATOR
Intervention: Open Nissen fundoplication
Number of subjects: 110
Study: 7957545

Group type: EXPERIMENTAL
Intervention: Amiloride 15 mg daily
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 3664330

Group type: EXPERIMENTAL
Intervention: Ketoconazole (200 mg twice daily)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Nystatin (500,000 units four times daily)
Number of subjects: 51
Study: 29517578

Group type: EXPERIMENTAL
Intervention: Pilocarpine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27621237

Group type: EXPERIMENTAL
Intervention: Health Coaching (HC)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 351
Study: 25007860

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study: 22388343

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (0.8 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oral salbutamol (8 mg)
Number of subjects: 18
Study: 20029224

Group type: EXPERIMENTAL
Intervention: Metformin continued throughout pregnancy
Number of subjects: 197

Group type: COMPARATOR
Intervention: Control group (Metformin stopped in first trimester or conceived spontaneously without Metformin)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Metformin continued in women with prior history of miscarriage
Number of subjects: 197

Group type: COMPARATOR
Intervention: Control group (women with prior history of miscarriage)
Number of subjects: 197
Study: 18299779

Group type: EXPERIMENTAL
Intervention: heroin+methadone group
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: methadone-only group
Number of subjects: 2

Group type: COMPARATOR
Intervention: non-users
Number of subjects: 2
Study: 16222412

Group type: EXPERIMENTAL
Intervention: Blood Glucose Awareness Training (BGAT) for 2 months
Number of subjects: 111

Group type: COMPARATOR
Intervention: Physician-guided self-help control intervention
Number of subjects: 111